NCT04672330View on ClinicalTrials.gov

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

January 25, 2023

Study Completion Date

November 25, 2023

Conditions
Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma
Interventions
DRUG

Tislelizumab

Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）

Trial Locations (1)

200127

Shanghai Renji Hospital, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT04672330 - Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma | Biotech Hunter | Biotech Hunter